From the publishers of JADPRO
Metastatic Triple-Negative Breast Cancer
Resource Center
Menu
Resources
Videos
Videos
Fast Facts
Quizzes
News & Literature Highlights
Advertisement
News & Literature Highlights
The ASCO Post
Study Examines Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer
2022 ASCO Annual Meeting
The Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab in Patients With Locally Recurrent or Metastatic Triple-Negative Breast Cancer
2022 ASCO Annual Meeting
Apatinib Plus Etoposide as Second- or Higher-Line Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: A Single-Arm, Open Label, Prospective, Phase II Clinical Trial
2022 ASCO Annual Meeting
Treatment Advances in Metastatic Triple-Negative Breast Cancer (TNBC): Addressing the Knowledge Gap
2022 ASCO Annual Meeting
Real-World Data Comparing Third and Subsequent Line Regimens for Treatment of Metastatic Triple-Negative Breast Cancer in the United States
Epidemiology
Outcome of Patients With Metastatic Triple Negative Breast Cancer Treated With First-Line Chemotherapy: A Single Institution Retrospective Analysis
JNCCN
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer
Cancer and Metastasis Review
Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer
World Journal of Clinical Oncology
Overview of Recent Advances in Metastatic Triple Negative Breast Cancer
International Journal of Molecular Sciences
Multi-Gene Testing Overview With a Clinical Perspective in Metastatic Triple-Negative Breast Cancer
Journal of Oncology Pharmacy Practice
Case Report of Sacituzumab Govitecan-hziy-Induced Neutropenia in a Patient With Metastatic Triple-Negative Breast Cancer and a Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 Poor Metabolizer Genotype
Scientific Reports
Addition of Immune Checkpoint Inhibitors to Chemotherapy Versus Chemotherapy Alone in First-Line Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
Nature Reviews Clinical Oncology
Immune-Checkpoint Inhibition for Metastatic Triple-Negative Breast Cancer: Safety First?
ESMO Open
How I Treat Metastatic Triple-Negative Breast Cancer
Breast Cancer: Targets and Therapy
Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective
New England Journal of Medicine
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Asia-Pacific Journal of Clinical Oncology
Metastatic Triple Negative Breast Cancer: Optimizing Treatment Options, New and Emerging Targeted Therapies
The ASCO Post
KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer
2021 San Antonio Breast Cancer Symposium
Datopotamab Deruxtecan in Advanced/Metastatic HER2- Breast Cancer: Results From the Phase 1 TROPION-Pantumor01 Study
Pharmaceuticals
Immunotherapy Treatment for Triple Negative Breast Cancer
Advertisement
Fast Facts
Fast Facts #2: Chemotherapy
Advertisement
Quizzes
Test your knowledge on molecular subtyping in TNBC
Test your knowledge on chemotherapy for mTNBC